How PBMs and Discount Cards Impact Generic Drug Prices (video)

Recently, I explored the complex web of relationships and conflicts that support today’s discount card economics. See The GoodRx-Kroger Blowup: Spread Pricing, Pharmacy Margins, and the Future of Discount Cards.

In the video below, I discuss how generic drug pricing and the rise of patient-paid, discount card prescriptions pose a risk to pharmacy benefit plans and the PBM business. I also highlight the odd relationship between Prime Therapeutics, Amazon Pharmacy, Express Scripts, and five Blues plans.

The video is excerpted from my PBM Industry Update: Trends, Controversies, and Outlook video webinar. If you missed the live event, you can register to watch a replay.

Enjoy!

Click here if you can’t see the video below.

P.S. Due to a technical snafu, we are only able to share an excerpt from the Zoom replay. This means that (1) the video is not high-definition, and (2) I appear in a small box in the upper right corner. (Of course, some viewers may prefer to see less of me...)